Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
| 1.4 | |
| 1.39 | |
| - | |
| 1.46 | |
| 1.38 | |
| 1.22-5.9355 | |
| 16 375 K | |
| 11 696 K | |
| 3 170 K | |
| 0.47 | |
| 0.842 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Synlogic Inc (NASDAQ:SYBX) announced an extended cash runway into the first half of 2025 following a $21.0 million public offering and a $2.5 million milestone payment from Roche. The company's pivota...
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal tri...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
